Journal
JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 31, Issue 8, Pages 1283-1285Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2017.05.010
Keywords
Glucagon-like peptide-1 receptor agonist; Type 2 diabetes; Basal insulin; Combination therapy; Clinical trial
Categories
Funding
- GlaxoSmithKline
Ask authors/readers for more resources
We have previously reported that once-weekly albiglutide was noninferior to thrice-daily lispro for glycemic lowering, with decreased weight and risk of hypoglycemia, in patients inadequately controlled on basal insulin over 26 weeks. Findings after 52 weeks reveal similar responses to albiglutide as an add-on to insulin glargine. (C) 2017 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available